Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
PRESSRELEASE September 6, 2022
AegirBio AB is pleased to announce that its abstract entitled "Quantitation of bivalent and monovalent natalizumab: providing a tool to study effects of IgG4 arm exchange." has been accepted for poster presentation at the upcoming ECTRIMS 2022 congress to be held in Amsterdam on the 26-28 of October 2022.
The ECTRIMS congress is the world's largest gathering of neurologists and scientists focused on Multiple Sclerosis (MS). In addition to planned marketing outreach, including a booth in the exhibition hall, the company will be hosting a "Brain Exchange". This open discussion session led by a panel of experts, including MS key opinion leader Dr John Foley, is tentatively titled "The case for therapeutic drug monitoring (TDM) of biologic therapies used in Multiple Sclerosis" and will explore personalized dosing in clinical practice.
All of these activities are designed to showcase AegirBio's recently approved point of care TDM test for natalizumab (originally launched by Biogen under the brand name Tysabri®), one of the leading drugs used to treat MS.
"It was at the 2019 ECTRIMS congress in Stockholm that our Chairman of the Board, Anders Ingvarsson, and I, then CEO of Abreos Biosciences, laid the foundations for what would become AegirBio. It is therefore exciting, 3 years later, to present our fully developed product to the MS community and to get first-hand feedback on its utility from future users" said Bradley Messmer, CEO of AegirBio. He added "Our approved product is the first of its kind and answers the current need for measurements of total natalizumab levels in treated patients. Our poster describes the next generation of the technology."
The company's poster presentation describes a novel use of our VeritopeTM platform to distinguish between the two forms of the drug molecule found in treated patients. This data may aid physicians in clinical decision making when using natalizumab in MS patients. A scientific manuscript on this topic has been accepted for peer reviewed publication in the journal "Therapeutic Drug Monitoring" and the technology is covered by a pending patent application.
More information about ECTRIMS 2022 can be found here: https://2022.ectrims-congress.eu/